Vepugratinib not checked

Eli Lilly · LY3866288 · LOXO-435

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
3 active
5 in total · 2 in the EU
Targets
 

What this is

How it works
Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
Tested for
Urinary Bladder Neoplasms (3 trials), Neoplasm Metastasis (2 trials), Carcinoma, Transitional Cell, Urologic Neoplasms, Receptor, Fibroblast Growth Factor, Type 3, Ureteral Neoplasms
Main trialPhase 3
“The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab. Study participation could last up to approximately 6 years.”In the company’s words, NCT07218380 on ClinicalTrials.gov
Other names
LY3866288 · LOXO-435

Other drugs for Urinary Bladder Neoplasms

All 85 drugs for Urinary Bladder Neoplasms

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Oct 2029 A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Phase 2Not yet recruiting Jul 2028 A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer
Phase 1Recruiting Jun 2027 FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Phase 1Completed 2 Dec 2024 A Study of LY3866288 in Healthy Participants
Phase 1Completed 3 Jan 2025 A Study of [14C]-LY3866288 in Healthy Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Vepugratinib

Following is part of Solo: you see every change to Vepugratinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in